Clinical Trial Update: Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating alefacept in relapsed or refractory cutaneous T-cell lymphoma and peripheral T-cell non-Hodgkin's lymphoma has completed with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Lymphoma
• Peripheral T-cell Non-hodgkin Lymphoma

Drugs mentioned

• Alefacept (Alefacept)

Snippet

Sponsor: Mayo Clinic | Conditions: Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2017-10-02